Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer - Report - MDSpire
Advertisement
Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer
Clinical Report: Evaluating the Necessity of Complete Adherence in NSCLC
Overview
This study assessed the long-term outcomes of completing perioperative chemoimmunotherapy in patients with resectable non-small cell lung cancer (NSCLC). Results indicated no significant differences in recurrence-free survival (P = 0.85) or overall survival (P = 0.34) between patients who completed the regimen and those who did not.
Background
Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality, with a significant proportion of patients experiencing recurrence post-surgery. Neoadjuvant chemoimmunotherapy has emerged as a standard treatment, yet high non-adherence rates pose challenges to its effectiveness. Understanding the impact of treatment completion on patient outcomes is crucial for optimizing therapeutic strategies.
Data Highlights
Group
Recurrence-Free Survival (P)
Overall Survival (P)
Adverse Events
Completed (n=37)
0.85
0.34
Higher incidence of any-grade AEs
Non-Completed (n=127)
No significant increase in Grade 3/4 AEs
Key Findings
No significant differences in recurrence-free survival (P = 0.85) between completed and non-completed groups.
No significant differences in overall survival (P = 0.34) between the two groups.
Positive pathological nodal status was an independent predictor of recurrence.
Completion status did not significantly affect recurrence risk (adjusted hazard ratio 1.14, P = 0.87).
The completed group had a higher incidence of any-grade adverse events.
Subgroup analysis indicated a recurrence benefit from completion in patients aged <65 years with ECOG score 0.
Clinical Implications
The findings suggest that while completing the perioperative chemoimmunotherapy regimen does not confer a significant survival advantage, it is associated with a higher incidence of adverse events. Clinicians should consider these factors when discussing treatment plans with patients.
Conclusion
The study highlights the need for further prospective research to clarify the role of treatment completion in improving outcomes for patients with resectable NSCLC.
